Insulin glargine doesn't affect cancer rate in diabetes

06/27/2013 | MedPage Today (free registration) · Healio

Insulin glargine did not increase the incidence of cancer in patients with prediabetes and diabetes, researchers reported at the ADA 73rd Scientific Sessions. Data showed the rate of cancer was 1.32 per 100 person-years in the glargine and standard care groups at six years, while the unadjusted rates of cancer-related mortality were 0.54 per 100 person-years in the standard group and 0.51 per 100 person-years in the glargine group.

View Full Article in:

MedPage Today (free registration) · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations